Company intelligence / Profile preview
ECM Therapeutics
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
Overview
ECM Therapeutics has developed patented extracellular matrix hydrogel technology with FDA-cleared solid-form ECM scaffolds already used in over 10 million patients for tissue repair. Their first clinical product, EsophaGel, is designed to treat Barrett’s esophagus—a precancerous condition with limited current therapies. Other applications are under development for musculoskeletal and cardiovascular repairs as well as non-healing wounds
- Therapeutic areas
- NeurologyDermatologyOphthalmologyGastroenterologyRheumatologyCardiovascular
- Modalities
- Hydrogel-based drug delivery therapyBiologicExtracellular matrix-based therapy (ECM bioscaffold)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on ECM Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ECM Therapeutics.